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Abstract
Background Various diagnostic tests are available to establish the primary aldosteronism (PA) diagnosis and to
determine the disease laterality. Combined with the controversies in the literature, unawareness of guidelines and
technical demands and high costs of some of these diagnostics, this could lead to significant differences in work-up
strategies worldwide. Therefore, we investigated the work-up before surgery for PA in daily clinical practice within a
multicenter study.
Methods Patients who underwent unilateral adrenalectomy for PA within 16 centers in Europe, Canada, Australia
and the USA between 2010 and 2016 were included. We did not exclude patients based on the performed diagnostic
tests during work-up to make our data representative for current clinical practice. Adherence to the Endocrine Society
Guideline and variables associated with not performing adrenal venous sampling (AVS) were analyzed.
Results In total, 435 patients were eligible. An aldosterone-to-renin ratio, confirmatory test, computed tomography
(CT), magnetic resonance imaging and AVS were performed in 82.9%, 32.9%, 86.9%, 17.0% and 65.3% of patients,
respectively. A complete work-up, as recommended by the guideline, was performed in 13.1% of patients. Bilateral
disease or normal adrenal anatomy on CT (OR 16.19; CI 3.50–74.99), smaller tumor size on CT (OR 0.06; CI
0.04–0.08) and presence of hypokalemia (OR 2.00; CI 1.19–3.32) were independently associated with performing
AVS.
Conclusions This study is the first to examine the daily clinical practice work-up of PA within a worldwide cohort of
surgical patients. The results demonstrate significant variability in work-up strategies and low adherence to The
Endocrine Society guideline.
Introduction
Primary aldosteronism (PA) is the most common surgically
treatable cause of secondary hypertension with an esti-
mated prevalence of 5–20% within the hypertensive pop-
ulation [1–7]. In the vast majority of cases, PA is either
caused by bilateral adrenal hyperplasia or by a unilateral
aldosterone-producing adenoma (APA). While bilateral
hyperplasia is generally treated with a mineralocorticoid
receptor agonist, adrenalectomy is the preferred treatment
for patients with APA [8, 9].
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In 2008, The Endocrine Society published a clinical
practice guideline on PA with the goal of improving
screening, work-up and treatment of PA worldwide [8].
The guideline recommended the use of the aldosterone-to-
renin ratio (ARR) to detect cases of PA among hyperten-
sive patients. Due to the risk of false-positive ARRs, case
confirmation with a confirmatory test was recommended in
all patients with a positive ARR. Computed tomography
(CT) was recommended to exclude adrenocortical carci-
noma and in case surgery for PA was indicated, and adrenal
venous sampling (AVS) was recommended in all patients
to distinguish APA from bilateral hyperplasia [8]. In 2016,
an update of the Endocrine Society Guideline was pub-
lished [9]. This revised guideline suggested that a specific
subgroup of patients potentially do not have to undergo
confirmatory testing or AVS. However, these recommen-
dations were based on a relatively low level of evidence
[9].
Within the work-up to adrenalectomy in patients with
PA, however, a large variety of diagnostic tests and
imaging modalities are available to establish the PA
diagnosis and to determine laterality of disease. This is
reflected in the numerous controversies in the literature and
between experts in the field regarding the different preop-
erative work-up strategies. Currently, the most important
topic of discussion is whether all patients should undergo
confirmatory testing and AVS [10–12]. Moreover, these
diagnostics could be considered expensive, laborious or
technically demanding. Based on the above, we hypothe-
sized that clinicians might deviate from the Endocrine
Society guideline within current daily clinical practice.
In the past, complete cure of hypertension after the
operation was estimated in approximately 50% of patients
[13, 14]. However, recently the Primary Aldosteronism
Surgery Outcome (PASO) study group and our own study
group showed the less optimistic results by presenting a
27–37% cure rate within large, international and well-ex-
ecuted studies [12, 15, 16]. This stresses the need to
evaluate current practice with the goal to improve the
benefits of surgery. Since the present literature lacks data
on how the work-up to surgery is performed in daily
practice, we set out to evaluate and describe the performed
work-up within a worldwide cohort of patients who




We performed an international retrospective cohort study
across 16 referral medical centers in The USA, Europe,
Canada and Australia. The study cohort was established by
the International CONNsortium study group and the
derivation of the cohort and the blood pressure-related
outcomes has been described in previous publications
[15, 16]. In brief, all consecutive patients who underwent
unilateral total adrenalectomy for APA between 2010 and
2016 were included retrospectively. We did not include or
exclude patients based on the performed work-up strategy
and, therefore, the diagnosis of PA and indication for
surgery were based on the treating physicians’ assessment
and discretion. In the majority of cases, biochemical evi-
dence of PA was based on the ARR (or in some cases
single aldosterone) measurements. Confirmatory testing
was performed according to the physicians’ preference
and/or availability of this test within each medical center.
Unilateral disease was diagnosed based on CT and/or
magnetic resonance imaging (MRI) and/or AVS according
to the preference of the physician and/or availability of
these modalities within each medical center. Since the
cohort was initiated for a different study aim (i.e., to
describe the reduction in blood pressure and antihyper-
tensive medications after adrenalectomy), patients with
missing preoperative or follow-up data regarding systolic
blood pressure (SBP), diastolic blood pressure (DBP) or
corresponding number of antihypertensive medications
were not included in the cohort [15]. Data collection was
performed separately within each center with the use of a
standardized data-entry manual. Patient demographics,
disease characteristics, laboratory data (e.g., measurements
of ARR and confirmatory testing), results of CT/MRI/AVS,
operative characteristics, pathology diagnosis and timing of
follow-up were collected. Institutional review board
approval was obtained in all participating centers.
Outcomes
The primary aim of this study was to evaluate the adher-
ence to The Endocrine Society guideline for the work-up of
patients treated for PA [8]. As our cohort consisted of who
had an adrenalectomy before (or around) publication of the
most recent 2016 version of the guideline, we chose to
primarily compare our results to the guideline which was
published in 2008 [8]. Within the new 2016 guideline, only
two recommendations regarding work-up were introduced:
I. In case of hypokalemia, plasma renin levels below
detection levels and aldosterone above[20 ng/dL
(550 pmol/L), no confirmatory testing may be needed;
II. In case of age\35 years old, hypokalemia, marked
aldosterone excess and unilateral cortical adenoma on
CT, no AVS may be needed [9].
We additionally aimed to evaluate the potential influ-
ence of these new recommendations on clinical practice by
1906 World J Surg (2020) 44:1905–1915
123
examining the proportions of patients fulfilling/meeting
these criteria within our cohort.
The secondary aim of this study was to identify potential
disease or patient characteristics which encouraged clini-
cians to distinguish APA from bilateral hyperplasia and to
determine laterality of disease based on CT alone without
performing AVS.
Definitions
Due to the different assays and reference values within the
participating centers, we were not able to analyze absolute
values of biochemical measurements. To compare labora-
tory data between the centers, measurements were classi-
fied as elevated or suppressed when they were above the
upper or below the lower limit of the center’s local refer-
ence ranges, respectively. Marked aldosterone excess was
defined as an elevated aldosterone level, and hypokalemia
was defined as either a potassium level below the local
reference range or the use of potassium supplementation.
When the results of biochemical measurements (e.g., ARR
or confirmatory test) were not known within the operating
centers, the measurement was reported as not performed.
When these measurements were performed in other medi-
cal centers before referral, the results were reported within
the database. Complete cure of hypertension was defined
according to the PASO consensus criteria [12].
Statistical analysis
Normally and not normally distributed continuous data are
shown as mean (± standard deviation) and median (range).
To compare continuous variables between groups, the
Mann–Whitney U Test was used for not normally dis-
tributed data and independent samples t tests for normally
distributed data. The Chi-Square test and Fisher’s exact test
were used to analyze group differences for categorical
variables. To analyze potential variables associated with
not making use of AVS, we performed multivariable
logistic regression with backward stepwise selection
including variables with p\ 0.25 in univariable analysis.
Only patients who underwent CT were included in this
analysis. Multiple potential prognostic variables had
missing values. These variables were imputed using mul-
tiple imputation generating 20 imputed datasets [17].
Outcomes were not imputed. Pooled odds ratios with 95%
confidence intervals were obtained from multivariable
logistic regression. All tests were two-sided and p-values\
0.05 were considered significant. Statistical analysis was
performed using SPSS version 23.0 (Chicago, Illinois,
USA), and figures were constructed using Graphpad Prism
version 7.02 (GraphPad Software Inc, California, USA)
and Draw.io version 10.5-1 (JGraph Ltd, Northampton-
shire, UK).
Results
Four hundred and thirty-five (85%) patients were eligible
for analysis [15]. Baseline characteristics of these patients
are presented in Table 1. Most patients were men (57.2%).
The mean age and mean BMI were 50.7 ± 11.4 years and
29.7 ±6.0 kg/m2, respectively. Hypokalemia was present
in 73.9% of patients, and most patients had grade 1
hypertension (41.4%). Preoperative work-up data of these
patients are presented in Table 2. In 82.9% of patients, a
complete measurement of the ARR was performed and in
94.5% of these patients, the ARR was elevated indicating
PA. A confirmatory test was performed in 32.9% of all
patients, indicating PA in 89.5%. CT, MRI and AVS were
performed in 86.9%, 17.0% and 65.3% of the cohort,
respectively. Almost half of the patients (49.9%) under-
went both CT and AVS for subtype testing. CT only, MRI
Table 1 Baseline characteristics of 435 patients
Variable Number (%) or
mean ± SD
Age at surgery (years) 50.7 ± 11.4
Female 186 (42.8%)
Duration of hypertension (years)
(n = 366)*
9 (0–42)
Body mass index (kg/m2) (n = 402) 29.7 ±6.0
Number of antihypertensive medications 3 (0–8)
Defined daily dose (n = 405)* 3.7 (0.0–25.3)
Hypokalemia (n = 429) 317 (73.9%)
Preoperative mean SBP (mmHg) 150 ± 20
Preoperative mean DBP (mmHg) 90 ± 13
JNC/ESH hypertension grade based on blood pressure with
medication
Grade 0 111 (25.5%)
Grade 1 180 (41.4%)
Grade 2 105 (24.1%)






*Values not normally distributed given as medians (range)
JNC = Joint National Commission, ESH = European Society of
Hypertension, SBP = systolic blood pressure, DBP = diastolic blood
pressure, EPRA = endoscopic posterior retroperitoneal adrenalec-
tomy, ELRA = endoscopic lateral retroperitoneal adrenalectomy,
LTA = laparoscopic transabdominal adrenalectomy
World J Surg (2020) 44:1905–1915 1907
123
only and AVS only were used in 28.5%, 5.1% and 3.7% of
patients, respectively. Furthermore, CT combined with
MRI was used in 3.9% and MRI combined with AVS in
4.4% of patients. All three modalities were used in 4.6% of
patients (Fig. 1). As indicated in Fig. 2, large variability in
work-up strategies was observed between the different
medical centers. Depending on the medical center, the use
of a confirmatory test, CT and AVS ranged from 0.0 to
94.6%, 66.7 to 100.0% and 9.1 to 100.0% of patients,
respectively. All centers used AVS in some cases, and only
one center performed AVS in all cases. Furthermore, MRI
was used in all medical centers except one.
Adherence to the 2008 endocrine society guideline
Out of the 435 patients who underwent surgery for PA,
screening was performed by a complete ARR in 361
patients (83.0%) and in 341 patients (78.4%), this ARR
was elevated suggesting PA (Fig. 3). Of the patients
without a preoperative ARR, a preoperative aldosterone
measurement was performed in 63.5% of patients showing
elevated aldosterone levels in 72.3% of these patients. A
confirmatory test was performed in 114 of the 341 patients
with an elevated ARR (33.4%), and in 102 patients (29.9%)
the test indicated PA. Ninety-one of these 102 patients
(89.2%) underwent CT, and in 11 patients (10.8%) no CT
was performed. These 11 patients underwent MRI and/or
AVS. Sixty out of 91 patients (65.9%) also underwent
AVS, and in 57 (62.6%) patients the AVS indicated uni-
lateral disease. When combining these results, 57 out of the
435 (13.1%) patients who had surgery within this cohort
underwent the complete work-up as recommended by the
2008 Endocrine Society Guideline [8]. All other patients
did not undergo all recommended diagnostic modalities or,
for instance, had an ARR or confirmatory test not com-
patible with PA (Fig. 3). Complete cure of hypertension
after the operation was comparable between the 13.1% of
patients with the complete work-up and all other patients,
30% and 27%, respectively.
Table 2 Preoperative work-up
Variable Number (%)
Measurement of aldosterone performed 408 (93.8%)
Aldosterone elevated 225 (55.1%)
Measurement of renin performed 370 (85.1%)
Renin suppressed 245 (66.2%)
Measurement of ARR performed 361 (82.9%)
ARR elevated 341 (94.5%)
Confirmatory test performed 143 (32.9%)
Oral salt loading 18 (12.6%)
Saline infusion test 118 (82.5%)
Fludrocortisone suppression test 3 (2.1%)
Captopril challenge 1 (0.7%)
Fludrocortisone dexamethasone suppression test 1 (0.7%)
Post-low dose dexamethasone suppression—saline
infusion test
1 (0.7%)
Confirmatory test indicating PA
Yes 128 (89.5%)
No 13 (9.1%)
Missing data 2 (1.4%)
CT performed 378 (86.9%)
Unilateral disease 325 (86.0%)
Bilateral disease 28 (7.4%)
Normal adrenal anatomy 21 (5.6%)
Missing data 4 (1.1%)
MRI performed 72 (17%)
Unilateral disease 63 (87.5%)
Bilateral disease 3 (4.2%)
Normal adrenal anatomy 5 (6.9%)
Missing data 1 (1.9%)
AVS performed 284 (65.3%)
Unilateral disease 263 (92.6%)
Bilateral disease 7 (2.5%)
No lateralization 7 (2.5%)
Failure of procedure 6 (2.1%)
Missing data 1 (0.4%)
ARR = aldosterone-to-renin ratio, PA = primary aldosteronism,
CT = computerized tomography, MRI = magnetic resonance imag-
ing, AVS = adrenal venous sampling
Fig. 1 Imaging modalities used for subtype testing. CT = comput-
erized tomography, MRI = magnetic resonance imaging; AVS =
adrenal venous sampling
cFig. 2 Large heterogeneity in the use of confirmatory testing, MRI,
CT and AVS. CT = computerized tomography, MRI = magnetic
resonance imaging, AVS = adrenal venous sampling. Legend: This
figure shows the use of different diagnostic modalities in the work-up
of primary aldosteronism specified by continent and medical center.
As presented, a large variability in work-up strategies was used in
daily clinical practice and, in contrast to the guideline, confirmatory
testing and AVS were not regularly performed
1908 World J Surg (2020) 44:1905–1915
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Evaluation of the 2016 endocrine society guideline
Within the complete cohort, 177 patients (40.7%) preop-
eratively had known elevated aldosterone, suppressed renin
and spontaneous hypokalemia omitting the need for con-
firmatory testing according to the revised 2016 guideline.
Only 49 (18.9%) of the 258 patients that did not meet these
criteria underwent confirmatory testing. Among the 242
patients in whom a preoperative CT was performed, only
30 (12.4%) patients were younger than 35 years of age and
only 14 (5.8%) patients also had an elevated aldosterone,
spontaneous hypokalemia and a unilateral nodule on CT.
According to the 2016 guideline, these 5.8% of patients did
not have to undergo AVS [9].
Variables associated with performing AVS
Univariable analysis showed that AVS was more fre-
quently performed in case of older age, male gender, longer
duration of hypertension, presence of hypokalemia, CT
indicating bilateral disease or normal adrenal anatomy and
a smaller tumor on CT (Table 3). After multivariable
regression analysis, bilateral disease or normal adrenal
anatomy on CT (OR 16.19; CI 3.50–74.99) (p\ 0.001),
smaller tumor size on CT (mm) (OR 0.06; CI 0.04–0.08)
(p\ 0.001) and hypokalemia (OR 2.00; CI 1.19–3.32)
(p = 0.008) remained independently associated with per-
forming AVS.
Fig. 3 Work-up in current clinical practice in contrast to the Endocrine Society Guideline 2008. *2 patients had failure of AVS procedure
and in 1 patient AVS showed no lateralization. PA = primary aldosteronism, ARR = aldosterone-to-renin ratio, CT = computerized
tomography, MRI = magnetic resonance imaging, AVS = adrenal venous sampling. Legend: This figure describes the work-up to surgery for
primary aldosteronism in daily clinical practice as it was performed within this study cohort. The performed work-up was compared to the
2008 Endocrine Society Guideline as this was accurate during the inclusion period of the study. The figure shows low guideline adherence
since 13.1% underwent the complete work-up according to the guideline. Patients were excluded when: (1) they did not undergo one of the
recommended diagnostic test, (2) the results of the aldosterone-to-renin ratio and confirmatory test did not correlate with primary
aldosteronism, (3) the results of adrenal venous sampling did not indicate unilateral aldosterone hypersecretion (all indicated by the horizontal
arrows to the right)
1910 World J Surg (2020) 44:1905–1915
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Discussion
This study evaluated the work-up to adrenalectomy for PA
within current daily practice in an international retrospec-
tive cohort of surgical patients. The results displayed a
large variability in work-up strategies between the
participating centers worldwide. During the inclusion per-
iod of this study, the 2008 Endocrine Society Guideline
was applicable [8]. Only 13.1% of the operated patients
underwent a complete work-up as was recommended by
this guideline. Although almost all patients underwent CT
(or MRI), confirmatory testing and AVS were performed in
Table 3 Variables associated with performing AVS for subtype testing









OR (95% CI) p value OR (95% CI) p value
Age (years) 0.0 51.6 (11.0) 48.9 (11.1) 1.02 (1.00–1.04) 0.026 – NS
Gender 0.0
Male 153 (71.8%) 60 (28.2%) 2.18 (1.42–3.34) <0.001 – NS
Female 89 (53.9%) 76 (46.1%) 1 (ref)
Body mass index (kg/m2) 7.7 30.0 (6.2) 29.0 (6.2) 1.03 (0.99–1.06) 0.153 –
Duration of hypertension
(years)*
14.8 10 (0–40) 7 (0–38) 1.04 (1.01–1.08) 0.016 –
Systolic blood pressure
(mmHg)
0.0 150 ± 19 149 ± 18 1.00 (0.99–1.01) 0.635 NA NA
Diastolic blood pressure
(mmHg)
0.0 90 ± 12 88 ± 11 1.02 (1.00–1.04) 0.067 – NS
Number of antihypertensives* 0.0 3 (0–8) 3 (0–7) 1.03 (0.88–1.21) 0.846 NA NA
Defined daily dose* 6.6 3.7 (0.0–22.3) 3.2 (0.0–25.3) 1.03 (0.97–1.10) 0.332 NA NA
ARR indicating PA 16.9
Yes 187 (63.6%) 107 (36.4%) 1.75 (0.71–4.33) 0.223 – NS
No 10 (50.0%) 10 (50.0%) 1 (ref)
Elevated aldosterone 6.9
Yes 129 (66.2%) 66 (33.8%) 1.24 (0.80 – 0.331 NA NA
No 96 (61.1%) 61 (38.9%) 1.92) 1 (ref)
Suppressed renin 8.5
Yes 137 (64.6%) 75 (35.4%) 1.41 (0.88–2.26) 0.156 – NS
No 61 (56.5%) 47 (43.5%) 1 (ref)
Hypokalemia 1.3
Yes 188 (67.6%) 90 (32.4%) 1.88 (1.17–3.02) 0.009 2.00 (1.19–3.32) 0.008
No 50 (52.6%) 45 (47.4%) 1 (ref) 1 (ref)
CT outcome 1.1
Unilateral nodule 192 (59.1%) 133 (40.9%) 1 (ref) <0.001 1 (ref) <0.001




Bilateral nodule 26 (92.9%) 2 (7.1%)
Normal anatomy 21 (100%) 0 (0%)
CT tumor size (mm)* 6.8% 14 (0–29) 16 (6–95) 0.05 (0.04–0.07) <0.001 0.06 (0.04–0.08) <0.001
Bold values indicate statistical significance (p\ 0.05)
*Values not normally distributed given as medians (range)
**Variables with a p value\ 0.25 after univariable analysis were used for multivariable regression analysis with backward selection
ARR = aldosterone-to-renin ratio, PA = primary aldosteronism, CT = computerized tomography, AVS = adrenal venous sampling, OR = odds
ratio, CI = confidence interval, ref = reference variable, NS = not significant, NA = not applicable
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only one-third and two-third of the operated patients,
respectively. The results also showed a significant vari-
ability in work-up within the majority of centers. More-
over, this variability in work-up was also shown between
countries, between the centers within these countries and
within the individual centers. Therefore, this study illus-
trates that clinicians most likely chose a particular work-up
strategy, such as the selective use of AVS, based on their
preferences or guided by case specifics instead of following
the Endocrine Society or local guideline.
Currently, the ARR is the most reliable test for screen-
ing for PA [8, 9, 18, 19]. Confirmatory testing is recom-
mended for all patients with a positive ARR to exclude the
false-positive ARR results. However, this study shows the
large variability in diagnostic work-up worldwide in which
a confirmatory test was performed in only 32.9% of
patients. The relatively low proportion of patients who
underwent a confirmatory test and the large variability
between the centers could be due to the fact that all con-
firmatory tests have some limitations and no universally
accepted ‘‘gold standard’’ confirmatory test for PA is
identified in the current literature [20–26]. Additionally,
confirmatory tests are relatively expensive and frequently
difficult to perform in outpatient settings [8, 9]. This may
have contributed to the changes in the 2016 guideline. Our
data show that a relatively large proportion of patients
(40.7%) fulfills the triad of marked aldosterone, suppressed
renin and hypokalemia. Omitting confirmatory testing in
these patients would have been in agreement with the
revised guideline of 2016. Therefore, this change in the
guideline could induce a substantial reduction in confir-
matory testing. It should be noted that this revised rec-
ommendation was based on a relatively low level of
evidence, and therefore, not performing a confirmatory test
is not without risks, especially because a patient with pri-
mary hypertension could be incorrectly diagnosed with PA
and potentially undergo surgery based on the false-positive
ARR results. Nevertheless, the recently published study by
Umakasi et al. [27] supports the recommendation of
omitting confirmatory testing in case of aldosterone
excess[ 20 ng/dL (550 pmol/L), suppressed renin and
hypokalemia by presenting a PA diagnosis in 100% these
cases.
There seems to be no consensus between clinicians on
the use of AVS, as evidenced by the 34.7% of patients in
this study who did not undergo AVS. Proponents argue that
AVS should be considered as the ‘‘gold standard’’ for
subtype testing, because multiple studies have shown its
superiority over CT in determining disease lateralization.
In these studies, the results of CT were compared to AVS
as reference standard [11, 28, 29]. Opponents of AVS
argue on the practical difficulties such as higher costs and
the need of an interventional radiologist. This limits the
wide availability of AVS, because some centers do not
have the financial resources or expertise to perform AVS.
In addition, AVS is an invasive procedure and also has
failure and complication rates [10, 30, 31]. Furthermore,
they argue that no significant differences in outcomes, such
as antihypertensive medications or quality of life, were
observed between CT and AVS within a randomized trial
[32].
In this study, all participating medical centers used AVS
in at least some patients. This suggests that AVS was
available for all medical centers during some period of the
inclusion period. Hence, we speculate that clinicians most
likely chose to perform or not perform AVS based on their
preferences or guided by case specifics. AVS was more
frequently performed on patients with higher age, male
gender, longer duration of hypertension and preoperative
hypokalemia. Potentially, these represent the patients with
more severe hypertension and/or hyperaldosteronism since
some of these factors are also known as risk factors for less
favorable clinical outcomes after adrenalectomy
[12, 33, 34]. Furthermore, AVS was more frequently done
in case of smaller tumor size, bilateral disease or normal
adrenal anatomy on CT. Recently, Williams et al. also
showed that AVS was more frequently performed in case
of male gender and smaller tumor size on CT in univariable
analysis. Furthermore, they indicated that AVS was used
more often in case of lower blood pressure, higher ARR
and lower estimated glomerular filtration rate [35].
The results of multivariable analysis within our cohort
showed CT findings were independently associated with
performing AVS. The presence of bilateral disease or
normal adrenal anatomy on CT proved to be the most
important trigger for clinicians to use AVS in daily prac-
tice. Likewise, 96.1% of patients with bilateral disease or
normal adrenal anatomy on CT also underwent AVS. In
contrast, patients with a clear unilateral nodule on CT and
especially patients with larger tumors were less likely to
undergo AVS. This further supports that CT findings most
likely have the highest influence on the choice to perform
or not perform AVS in daily clinical practice. Furthermore,
hypokalemia proved to be independently associated with
performing AVS. Nevertheless, it should be noted that
Umakosi et al. [27] recently showed a higher percentage of
hypokalemia in patients with APA compared to bilateral
adrenal hyperplasia, 87% versus 21%, respectively.
Therefore, one could argue to perform AVS less frequently
in case of hypokalemia. This seems to be in line with the
2016 guideline allowing the omission of AVS in case of a
clear unilateral cortical adenoma on CT when this is
combined with hypokalemia, age\ 35 years and marked
aldosterone excess [9]. Within this study, only 6% of
patients met these conditions and, consequently, this new
1912 World J Surg (2020) 44:1905–1915
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recommendation only has marginal influence on daily
practice.
Additionally, this study shows that work-up and surgery
for PA also is performed in some centers with relatively
low volume compared to centers in which PA is a clinical
spearhead. This could have resulted in lower guideline
adherence due to lower expertise and could stress the
importance of further centralization of the treatment of PA.
Furthermore, the low adherence can be due to the variety of
diagnostic tests available of which some can be considered
expensive, laborious or technically demanding. Also, it has
been reported that it takes an average of 17 years for
research evidence to reach clinical practice and, therefore,
time to adoption of guidelines can take up to years or
decades [36].
This study has some limitations. Similar to the majority
of studies on PA, the retrospective design is a weakness. As
a result, this study is more prone to missing data compared
to prospective studies. Potentially, this could have led to
lower rates of performed preoperative measurements of the
ARR and confirmatory testing, as we chose to classify
these modalities as not performed when the results were
not known within the local patient files or referral letters.
On the other hand, the retrospective design most likely is
appropriate to evaluate different types of work-up strate-
gies in clinical practice, as it reduces the influence of study
protocols on decisions made by clinicians and therefore
reflects daily practice. Because this is a surgical cohort,
medically treated patients were not included. Therefore, we
do not know if the results are representative for the med-
ically treated PA population. Due to the different labora-
tory assays and reference values within the participating
centers, we chose to not analyze absolute values of bio-
chemical measurements. Therefore, marked aldosterone
excess was defined as an aldosterone level above the local
reference range, instead of the [ 20 ng/dL (550 pmol/L)
cutoff suggested with the 2016 guideline [9]. Conse-
quently, this could have influenced the 40.7% of patients
meeting the criteria for omission of confirmatory testing.
The blood pressure-related outcomes within this cohort
were published earlier and therefore not reported within
this manuscript [15, 16]. As presented within these and
other recently published studies, complete cure of hyper-
tension after the operation is far from a certainty
[12, 15, 16, 37]. Potentially, this is due to the large vari-
ability in work-up strategies which stresses the importance
of evaluating how we currently perform the work-up to
surgery for PA. Although this study showed no difference
in cure of hypertension between patients with and without a
work-up as recommended by the guidelines, our study
cohort actually is not suitable for properly investigating the
potential influence of the presented uniformity in work-up
strategies on the outcomes after surgery. This is due to the
retrospective design which is prone to confounding by
indication.
In conclusion, this study examined the work-up to sur-
gery for PA within current worldwide daily clinical prac-
tice. The results demonstrate large variability in work-up
strategies both within and between the medical centers
resulting in relatively low guideline adherence. If we want
to further improve the benefits of surgery for PA in the
future, we should strive for a more uniform work-up to
surgery worldwide.
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